JP2012501351A5 - - Google Patents

Download PDF

Info

Publication number
JP2012501351A5
JP2012501351A5 JP2011525283A JP2011525283A JP2012501351A5 JP 2012501351 A5 JP2012501351 A5 JP 2012501351A5 JP 2011525283 A JP2011525283 A JP 2011525283A JP 2011525283 A JP2011525283 A JP 2011525283A JP 2012501351 A5 JP2012501351 A5 JP 2012501351A5
Authority
JP
Japan
Prior art keywords
key
type
site
composition
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011525283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012501351A (ja
JP5707326B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/055608 external-priority patent/WO2010027973A1/en
Publication of JP2012501351A publication Critical patent/JP2012501351A/ja
Publication of JP2012501351A5 publication Critical patent/JP2012501351A5/ja
Application granted granted Critical
Publication of JP5707326B2 publication Critical patent/JP5707326B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011525283A 2008-09-02 2009-09-01 ヒトパピローマウイルス/Ii−keyのハイブリッドおよびその使用方法 Expired - Fee Related JP5707326B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9360608P 2008-09-02 2008-09-02
US61/093,606 2008-09-02
US16990809P 2009-04-16 2009-04-16
US61/169,908 2009-04-16
PCT/US2009/055608 WO2010027973A1 (en) 2008-09-02 2009-09-01 Human papillomavirus / li-key hybrids and methods of use

Publications (3)

Publication Number Publication Date
JP2012501351A JP2012501351A (ja) 2012-01-19
JP2012501351A5 true JP2012501351A5 (enExample) 2012-10-18
JP5707326B2 JP5707326B2 (ja) 2015-04-30

Family

ID=41797447

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011525283A Expired - Fee Related JP5707326B2 (ja) 2008-09-02 2009-09-01 ヒトパピローマウイルス/Ii−keyのハイブリッドおよびその使用方法

Country Status (5)

Country Link
US (1) US8748130B2 (enExample)
EP (1) EP2344191A4 (enExample)
JP (1) JP5707326B2 (enExample)
CA (1) CA2731444A1 (enExample)
WO (1) WO2010027973A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009317691A1 (en) * 2008-11-21 2010-05-27 Kobenhavns Universitet (University Of Copenhagen) Priming of an immune response
EP2883550A1 (en) 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
CN110914295B (zh) * 2017-06-28 2024-08-09 里珍纳龙药品有限公司 抗人乳头瘤病毒(hpv)抗原结合蛋白及其使用方法
KR20210005646A (ko) * 2018-04-26 2021-01-14 아게누스 인코포레이티드 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100257941B1 (ko) * 1992-03-06 2000-06-01 휴버스윗 에이치. 밴 면역학적으로 중요한 에피토프에 상응하는 펩티드의 측정 방법 및 면역학적으로 중요한 에피토프에 상응하는 항체 또는 비오티닐화된 펩티드의 측정 방법에 상기 펩티드를 사용하는 방법, 상기 펩티드의 제조 방법 및 상기 펩티드를 함유하는 조성물
AU5670194A (en) * 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5559028A (en) * 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
EP0800545B2 (en) * 1995-11-01 2011-03-02 Bracco Research S.A. Targeted magnetically labeled molecular marker systems for the nmr imaging
AU3307497A (en) 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
US6432409B1 (en) 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
AU2003284239B2 (en) * 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
US20080095798A1 (en) * 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
AU2008269721B2 (en) * 2007-05-31 2013-01-10 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal HPV peptide vaccination
US7750588B2 (en) 2007-06-29 2010-07-06 Faurecia Automotive Seating Canada Limited Method of counting drive motor rotations, and memory modules, storage media, and motor and vehicle apparatuses utilizing same

Similar Documents

Publication Publication Date Title
CN111217917B (zh) 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法
JP2008529558A5 (enExample)
JP2013501038A5 (enExample)
EP3463444B1 (en) Improvement of hpv l2 peptide immunogenicity
JP2008530245A5 (enExample)
JP2019506175A5 (enExample)
JP2008505985A5 (enExample)
JP2012515557A5 (enExample)
JP2012516140A5 (enExample)
WO2024140767A1 (zh) 用于预防或治疗hpv感染相关疾病的多核苷酸分子
JP2010506926A5 (enExample)
CN101952320B (zh) 具有免疫原性的物质
Gissmann et al. Therapeutic vaccines for human papillomaviruses
JP2005512518A5 (enExample)
JP2008539164A5 (enExample)
JP2006507797A5 (enExample)
JP2011521648A5 (enExample)
JP2002516662A5 (enExample)
JP5707326B2 (ja) ヒトパピローマウイルス/Ii−keyのハイブリッドおよびその使用方法
CN101880328A (zh) 微小隐孢子虫Th多表位基因和融合蛋白及其应用
CN116731192A (zh) 重组刺突蛋白及其制备方法和用途
US11547753B2 (en) Cutaneous papilloma virus vaccine
WO2026046081A1 (zh) 一种牛结节性皮肤病病毒重组嵌合抗原及其制备方法和应用
CN121378498A (zh) 一种尼帕/亨德拉病毒重组抗原、其制备方法及应用
JP2014503174A5 (enExample)